Introduction Metabolic syndrome (MetS) is a combination of abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose. MetS patients have higher chances of developing insulin resistance, visceral adiposity, atherogenic dyslipidemia, and thus coronary artery disease and stroke. Alteration of platelet indices in diabetes mellitus, atherosclerosis, and other proinflammatory states has been described in multiple studies. Thus, this study was carried out to assess platelet indices in MetS.
Objectives This study was carried out to assess platelet indices in MetS.
Methods A cross-sectional study was carried out at Acharya Vinoba Bhave Rural Hospital, a tertiary care center over a period of 2 months from June 1, 2018 to July 31, 2018. Fifty patients diagnosed as having MetS, and 50 healthy controls were chosen. Estimation of anthropometric parameters including waist circumference; measurement of blood pressure; biochemical parameters including lipid profile; and platelet indices including plateletcrit, mean platelet volume (MPV), and platelet distribution width (PDW) were carried out.
Statistical Analysis Statistical analyses were carried out using inferential statistics, including chi-square test and Student's unpaired t-test, and software SPSS version 22.0 (IBM Corporation, Armonk, New York, United States) with GraphPad Prism version 6.0 (Informer Technologies, Inc. Los Angeles, California, United States) was used, with p < 0.05 being considered as significant.
Results A statistically significant, positive correlation was found between the waist circumference, systolic blood pressure, serum triglyceride levels, and plateletcrit, with the MetS status of patients (p < 0.05).
Conclusion This study revealed that MetS is a proinflammatory and prothrombotic state, characterized by alteration of platelet indices. Plateletcrit was shown to be a statistically significant biomarker along with other parameters such as waist circumference, systolic blood pressure, and serum triglyceride levels. Early detection and follow-up of patients using these markers can lead to an overall decline in morbidity and mortality owing to MetS.